USFDA Approval Alert! Indoco Remedies Expands Its US Portfolio with Allopurinol 200 mg

Indoco Remedies Ltd has received final approval from the US Food and Drug Administration (USFDA) for its Allopurinol Tablets USP 200 mg, marking a significant milestone in the company’s US generics strategy. Allopurinol, a xanthine oxidase inhibitor, is widely prescribed for the management of gout and certain types of kidney stones, and is also used to control uric acid levels in cancer therapy patients.

Regulatory Milestone:
Indoco Remedies’ Allopurinol 200 mg tablets have been approved under the Abbreviated New Drug Application (ANDA) pathway, allowing the company to manufacture and market the product in the US.

Therapeutic Use:
Allopurinol is indicated for adults with primary or secondary gout, patients with leukemia, lymphoma, or solid tumors undergoing cancer therapy that elevates uric acid, and those with recurrent kidney stones due to high uric acid excretion.

Product Strengths and Portfolio:
Indoco has previously received approvals for Allopurinol 100 mg and 300 mg tablets. The addition of the 200 mg strength enhances its product offering and competitive position in the US generics market.

WHO Essential Medicine:
Allopurinol is listed as an essential medicine by the World Health Organization, underscoring its importance in global healthcare.

Manufacturing and Exports:
The approved tablets will be manufactured at Indoco’s Goa facility, which has a strong compliance track record and has recently cleared multiple USFDA inspections.

Market Impact:
The US market for Allopurinol is sizable, with several generic players. Indoco’s entry with the 200 mg strength is expected to bolster its US revenue streams and support its broader international growth ambitions.

With this latest USFDA approval, Indoco Remedies continues to strengthen its presence in the US generics space, reaffirming its commitment to delivering high-quality, affordable medicines to patients worldwide.

Sources: DailyMed, New Drug Approvals, Business Standard